Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Saved in:
| Title: | Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. |
|---|---|
| Authors: | Jensen TO; Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Grandits GA; Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA., Jain MK; Southwestern Medical Center, University of Texas, Dallas, Texas USA., Murray TA; Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA., Grund B; School of Statistics, University of Minnesota, Minneapolis, Minnesota, USA., Shaw-Saliba K; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Matthay MA; Division of Pulmonary and Critical Care Medicine, University of California SanFrancisco, San Francisco, California, USA., Abassi M; Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Ardelt M; Division of Pulmonary and Critical Care Medicine, University of California SanFrancisco, San Francisco, California, USA., Baker JV; Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA.; Division of Infectious Diseases, Hennepin Healthcare, Minneapolis, Minnesota, USA., Chen P; Women's Guild Lung Institute, Department of medicine and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA., Dewar RL; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Goodman AL; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.; Department of Infectious Diseases, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom., Hatlen TJ; Lundquist Institute, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA., Highbarger HC; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Holodniy M; Department of Medicine, Infectious Diseases, Stanford University, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Lallemand P; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Laverdure S; Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Leshnower BG; Division of Cardiothoracic Surgery, Emory School of Medicine, Atlanta, Georgia, USA., Looney D; Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA., Moschopoulos CD; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Mugerwa H; Joint Clinical Research Centre, Kampala, Uganda., Murray DD; Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Mylonakis E; Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA., Nagy-Agren S; Salem Veterans Affairs Medical Center, Virginia, USA.; Virginia Tech Carilion School of Medicine, Virginia, USA., Rehman MT; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Rupert A; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Stevens RA; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Turville S; The Kirby Institute, University of New South Wales, Sydney, Australia., Weintrob A; Infectious Diseases Section, Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, USA., Wick K; Department of Internal Medicine, University of California Davis, Davis, California, USA., Lundgren J; Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Ko ER; Division of General Internal Medicine, Department of Medicine, Duke University Health System, Durham, North Carolina, USA. |
| Corporate Authors: | ACTIV-3/TICO Study Group |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 Mar 14; Vol. 229 (3), pp. 671-679. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiad446 |
